Akero Therapeutics (AKRO) Tops Q2 EPS by 1c

Akero Therapeutics (NASDAQ: AKRO) reported Q2 EPS of ($0.60), $0.01 better than the analyst estimate of ($0.61).

For earnings history and earnings-related data on Akero Therapeutics (AKRO) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch